Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

Jacqueline Vuky; Christina Isacson; Mehran Fotoohi; Jason Dela Cruz; Henry Otero; Vincent Picozzi; Thomas Malpass; David Aboulafia; Andrew Jacobs

doi:10.1007/s10637-005-4543-z

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

Jacqueline Vuky, Christina Isacson, Mehran Fotoohi, Jason Dela Cruz, Henry Otero, Vincent Picozzi, Thomas Malpass, David Aboulafia, Andrew Jacobs

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70%, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28%) and Grade II renal insufficiency (14%). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7%) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.

Original language	English (US)
Pages (from-to)	85-88
Number of pages	4
Journal	Investigational New Drugs
Volume	24
Issue number	1
DOIs	https://doi.org/10.1007/s10637-005-4543-z
State	Published - Jan 2006
Externally published	Yes

Keywords

Imatinib (Gleevec®)
Metastatic renal cell carcinoma
Phase II trial

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/s10637-005-4543-z

Cite this

@article{23d2fda22db74c77b3fe3505db03cc4d,

title = "Phase II trial of imatinib (Gleevec{\textregistered}) in patients with metastatic renal cell carcinoma",

abstract = "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70%, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28%) and Grade II renal insufficiency (14%). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7%) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.",

keywords = "Imatinib (Gleevec{\textregistered}), Metastatic renal cell carcinoma, Phase II trial",

author = "Jacqueline Vuky and Christina Isacson and Mehran Fotoohi and {Dela Cruz}, Jason and Henry Otero and Vincent Picozzi and Thomas Malpass and David Aboulafia and Andrew Jacobs",

note = "Funding Information: Supported by Novartis Pharmaceuticals. The authors would like to thank Cory Lang, R.N. and Lorrie Rasmussen, R.N. for nursing support.",

year = "2006",

month = jan,

doi = "10.1007/s10637-005-4543-z",

language = "English (US)",

volume = "24",

pages = "85--88",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

AU - Vuky, Jacqueline

AU - Isacson, Christina

AU - Fotoohi, Mehran

AU - Dela Cruz, Jason

AU - Otero, Henry

AU - Picozzi, Vincent

AU - Malpass, Thomas

AU - Aboulafia, David

AU - Jacobs, Andrew

N1 - Funding Information: Supported by Novartis Pharmaceuticals. The authors would like to thank Cory Lang, R.N. and Lorrie Rasmussen, R.N. for nursing support.

PY - 2006/1

Y1 - 2006/1

N2 - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70%, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28%) and Grade II renal insufficiency (14%). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7%) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.

AB - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70%, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28%) and Grade II renal insufficiency (14%). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7%) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.

KW - Imatinib (Gleevec®)

KW - Metastatic renal cell carcinoma

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=31544474604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544474604&partnerID=8YFLogxK

U2 - 10.1007/s10637-005-4543-z

DO - 10.1007/s10637-005-4543-z

M3 - Article

C2 - 16380835

AN - SCOPUS:31544474604

SN - 0167-6997

VL - 24

SP - 85

EP - 88

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this